Concepedia

Shweta Urva

SU

Statistics

Publications

29

Citations

3.7K

H-Index

20

Active since

2009

Affiliations

Eli Lilly (United States)(Current)

Novartis (United States)

University at Buffalo, State University of New York

St. Josef-Hospital

Novartis (Switzerland)

Shweta Urva is an author at Eli Lilly (United States) specializing in pharmacology, medicine, and diabetes mellitus.

ORCID

Publications per year

2009–2025

29

Publications

29

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

Tamer Coşkun, Kyle W. Sloop, Corina Loghin et al. · Molecular Metabolism · 2018 · 822 citations · Full text

, , +17

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Juan P. Frías, Michael A. Nauck, Joanna Van et al. · The Lancet · 2018 · 799 citations

, , +17

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

Francis S. Willard, Jonathan D. Douros, M Gabe et al. · JCI Insight · 2020 · 487 citations · Full text

, , +17

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

Tamer Coşkun, Shweta Urva, William C. Roell et al. · Cell Metabolism · 2022 · 276 citations · Full text

, , +17

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

Juan P. Frías, Michael A. Nauck, Joanna Van et al. · Diabetes Obesity and Metabolism · 2020 · 206 citations · Full text

, , +14

1–5 of 29